BioCryst Pharmaceuticals
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products:...
Latest News
3 days ago · globenewswire.com
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting— Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy —
6 days ago · zacks.com
4 Commercial-Stage Biotechs Poised for Sustained Revenue GrowthTGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
12 days ago · seekingalpha.com
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call TranscriptBioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Nick Wilder - Manager of Investor Relations Charles Gayer - CEO, President & Director Babar Ghias - CFO & Head of Corporate Development Sandeep Menon - Chief Research & Development Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Laura Chico - Wedbush Securities Inc., Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Stacy Ku - TD Cowen, Research Division Jeremiah Lorentz - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the BioCryst Third Quarter 2026 Earnings Call.
13 days ago · marketbeat.com
BioCryst Pharmaceuticals Q3 Earnings Call HighlightsBioCryst Pharmaceuticals NASDAQ: BCRX reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while maintaining its full-year ORLADEYO revenue outlook following a specialty-pharmacy transition.
13 days ago · zacks.com
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue EstimatesBioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.06 per share a year ago.
13 days ago · globenewswire.com
BioCryst Reports Third Quarter 2026 Financial Results— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — — Improved Non-GAAP operating expense guidance to $415 to $425 million — — Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older — RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended September 30, 2026, and provided a business update.
18 days ago · zacks.com
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?The consensus price target hints at a 137.9% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
20 days ago · zacks.com
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseBioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
26 days ago · globenewswire.com
BioCryst to Report Third Quarter 2026 Financial Results on November 4RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November 4, 2026.
1 month ago · globenewswire.com
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth—Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BCRX